Psychedelics

3D Systems Corporation investors with losses are encouraged to contact the firm before June 8, 2021; click here to submit trade information

Amdocs Limited investors with losses are encouraged to contact the firm before June 8, 2021; click here to submit trade information

Champignon Brands investors with losses are encouraged to contact the firm before June 9, 2021; click here to submit trade information

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of 3D Systems Corporation (NYSE: DDD) investors that acquired shares between May 6, 2020 and March 1, 2021. Investors have until June 8, 2021 to seek an active role in this litigation.

A class action lawsuit has also been filed on behalf of Amdocs Limited (NASDAQ: DOX) investors that acquired shares between December 13, 2016 to March 30, 2021. Investors have until June 8, 2021 to seek an active role in this litigation.

A class action lawsuit has also been filed on behalf of Champignon Brands, Inc. (OTC: SHRMF) investors that acquired shares between December 13, 2016 to March 30, 2021. Investors have until June 9, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or by clicking the above links.

3D Systems Corporation

3D Systems issued a press release on March 1, 2021 advising investors that it would delay the filing of its annual report on a Form 10-K. 3D systems stated that "the delay in filing is primarily related to the presentation of cash flows associated with the divestiture process for its Cimatron and GibbsCam software businesses." 3D Systems also stated that they had identified "certain internal control deficiencies" and that, as a result, it would "report material weaknesses in internal controls in its fiscal 2020 Annual Report on Form 10-K." 3D Systems filed a NT-10-K with the SEC on March 2, 2021, which statec that their 10-K filing would be delayed. On this news, 3D Systems' stock price declined by $7.62 per share, or more than 19.6%, on this news, from closing at $38.79 per share on March 1, 2021 to close at $31.17 per share on March 2, 2021, damaging investors. The lawsuit alleges that throughout the Class Period defendants made misleading and/or false statements and/or failed to disclose that: (1) 3D Systems lacked the proper internal controls over financial reporting; and (2) 3D Systems' public statements were materially false and/or misleading at all relevant times, as a result.

Amdocs Limited

It is alleged in this complaint that Amdocs issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Amdocs is the subject of a report published on March 31, 2021 by Jehoshaphat Research. According to the report, Amdocs overstated its profitability. Jehoshaphat alleges that Amdoc replaced reputable auditors with "scandal-plagued or tiny shops." It is alleged that Amdoc "window-dressed" its balance sheet in order to hide its borrowing. The report quotes a former Amdoc executive as saying, "The US business was declining at a rate of [around] 7% annually...but then we would see the company [publish results that] say North America is stable."

Champignon Brands, Inc.

It is alleged in this complaint that Champignon made misleading and false statements to the market. Sufficient internal controls over financials were not maintained by Champignon. Champignon issued financial statements that were false and could not be relied upon, requiring restatement. Champignon engaged in acquisitions with undisclosed third parties, and as a result, the British Columbia Securities Commission would suspend Champignon from trading. Champignon's public statements were materially misleading and false throughout the class period, as a result. Investors suffered damages when the market learned the truth about Champignon.

Class action lawsuits have already been filed. If you wish to serve as lead plaintiff in cases against 3D Systems Corporation or Amdocs Limited, you must move the Court no later than June 8, 2021. If you wish to serve as lead plaintiff in the case against Champignon Brands you must move the Court no later than June 9, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.

Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.

Love Pharma Inc. ("LOVE" or the "Company") (CSE:LUV)(FSE:G1Q0) is pleased to announce that it has entered into a definitive agreement (the "Agreement") to acquire Doc Hygiene Pharmaceuticals Inc. ("Doc Hygiene") for aggregate consideration of US$300,000 (the "Acquisition"). Doc Hygiene has a premium hygiene product line and brand for hygiene and sanitizing needs and a robust e-commerce platform for products and SKU's

"We are thrilled to announce the acquisition of Doc Hygiene," said Zach Stadnyk, CEO of LOVE. "We are extremely excited about Doc Hygiene's growth potential in the years ahead and firmly believe it will provide a parallel revenue stream to our existing business in over-the-counter products. Through this acquisition, the company now has a strong online e-commerce platform that will strengthen its product offering and ease of operational online sales from both a B2C and B2B standpoint."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and distribute additional psychedelic substances, most notably MDMA, under the amended terms outlined in its June 20, 2022 application to Health Canada.

Under the leadership of Chief Science Officer Justin Kirkland, Optimi will now act as wholesale supplier of MDMA and other synthetic psychedelic compounds to approved researchers and drug developers.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn') to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.

Awakn's proprietary ketamine-assisted therapy for the treatment of Alcohol Use Disorder was developed and validated in a Phase II a/b trial, with results announced in the American Journal of Psychiatry in January 2022. The trial delivered 86% abstinence over the six-month period post treatment versus 2% pre-trial and 25% in the current standard of care.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn enters the U.S. addiction treatment and relapse prevention market

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) ("Revitalist"), one of the largest publicly listed U.S. based ketamine wellness-clinic chains. The agreement will enable Revitalist to treat clients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Philip Young, CEO of Lobe Sciences stated, "We are extremely happy to have partnered with iNGENū as we move our proprietary stable psilocin products into human clinical trials. iNGENū is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO's in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Blue Serenity brings science and compassion together, will cement Thomas Hartle's legacy as a Canadian psychedelic icon

Optimi and Hartle to host press conference today at 1:00 PM EST

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×